CRISPR Therapeutics AG
CRSP · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $3.51M | $37.3M | −90.6% |
| Operating income | −$665M | −$467M | −42.4% |
| Net income | −$582M | −$366M | −58.8% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 2, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $12.7M | $900K | +1,311% |
| Operating income | −$130M | −$132M | +1.6% |
| Net income | −$111M | −$106M | −4.7% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was CRISPR's revenue in FY2025?
- $3.51M in FY2025 (Fiscal year ended Dec 31, 2025), −90.6% vs $37.3M a year earlier, per its 10-K filed Feb 2026.
- Was CRISPR profitable in FY2025?
- No: net income was −$582M and operating income −$665M in FY2025.
- What was CRISPR's revenue in Q3 2026?
- $12.7M (+1,311% vs a year earlier), per its Form 10-Q filed Nov 2, 2026.